P-257: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma: EXCALIBER-RRMM — Sagar Lonial (2022) | RDL Network
P-257: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma: EXCALIBER-RRMM
Sagar Lonial, Hang Quach, Meletios A Dimopoulos, Paula Rodríguez‐Otero, Jesús G. Berdeja, Paul G. Richardson, Margee Kyada, Shuyu Chu, Min Chen, Patricia C. Abad, Juliane Morando, Niels W.C.J. van de Donk
Sagar Lonial, Meletios A Dimopoulos, Jesús G. Berdeja, Paul G. Richardson, Hang Quach, Paula Rodríguez‐Otero, Paulo Maciag, Kevin Hong, Michael Amatangelo, Min Chen, Niels W.C.J. van de Donk
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, NJ Bahlis, Neil Rabin, Robert Z. Orlowski, M. Komarnicki, Kazuyuki Suzuki, Trine Lindhardt Plesner
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, NJ Bahlis, Neil Rabin, Robert Z. Orlowski, M. Komarnicki, Kazuyuki Suzuki, Trine Lindhardt Plesner
Paul G. Richardson, Michael Amatangelo, James R. Berenson, Claudio Cerchione, Meletios A Dimopoulos, Charlotte Toftmann Hansen, Soo Jeong Hwang, Phillip J. Koo, Junya Kuroda, Albert Oriol, Robert Z. Orlowski, Hang Quach, Marc S. Raab, Alberto Rocci, Yue Wang, Darrell White, Brian Yu, Zehua Zhou, Jessica Katz
Discussion(0)
No comments yet. Be the first to comment.